LCB 07A
Alternative Names: LCB-07ALatest Information Update: 14 Mar 2022
Price :
$50 *
At a glance
- Originator LegoChem Biosciences
- Class Antibodies; Antineoplastics; Drug conjugates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Haematological malignancies; Solid tumours
Most Recent Events
- 16 Feb 2022 LCB 07A is available for licensing as of 16 Feb 2022. https://www.legochembio.com/rnd/partners.php?lang=e
- 16 Feb 2022 Early research in Haematological malignancies in South Korea (Parenteral) (LegoChem Biosciences pipeline, February 2022)
- 16 Feb 2022 Early research in Solid tumours in South Korea (Parenteral) (LegoChem Biosciences pipeline, February 2022)